How effective is ritexitinib in treating alopecia areata?

Ritlecitinib (Ritlecitinib) is mainly used to treat alopecia areata and vitiligo, and has also shown efficacy in ulcerative colitis and Crohn's disease in clinical trials. Specifically, it was approved in the United States on June 23, 2023, for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older.

Ritexitinib irreversibly inhibits Janus kinase 3 (JAK3) and tyrosine kinases expressed in the hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In a cellular context, ritexitinib inhibits JAK3-dependent receptor-mediated cytokine-induced STAT phosphorylation and inhibits immune receptor signaling that is dependent on members of the TEC kinase family.

The U.S. FDA's approval of ritixitinib is based on the Phase 2b/3 ALLEGRO trial, which enrolled 718 patients with scalp hair loss of 50% or greater as measured by the Severity of Hair Loss Tool (SALT) and evaluated the efficacy and safety of ritixitinib at 118 sites in 18 countries. In the pivotal study, 23% of patients treated with ritixitinib 50 mg had scalp hair coverage of 80% or more (SALT≤20) after 6 months, compared with 1.6% of patients in the placebo group. The efficacy and safety of ritixitinibare consistent among adolescents (12 to 17 years of age) and adults (18 years of age and older).xa0

Overall, ritixitinib has some potential in treating vitiligo, but the specific effects will vary based on individual differences. Patients should consult a professional doctor before use and strictly follow medical instructions to ensure safe and effective treatment. At the same time, for the sake of physical health, patients also need to maintain good living habits and mood, and avoid scratching the affected area to avoid affecting the treatment effect.